A Call for Caution in Prescribing Gabapentin to Individuals With Concurrent Polysubstance Abuse: A Case Report
| Autor: | Jendayi Olabisi, Gabriel M Martinez, Laura Ruekert, Syed Hasan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
medicine.medical_specialty Gabapentin Substance-Related Disorders media_common.quotation_subject medicine.medical_treatment Pregabalin Food and drug administration 03 medical and health sciences 0302 clinical medicine medicine Humans Psychiatry media_common Controlled substance Epilepsy Postherpetic neuralgia business.industry Addiction medicine.disease 030227 psychiatry Anticonvulsant Polysubstance dependence Anticonvulsants Female business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of Psychiatric Practice. 25:308-312 |
| ISSN: | 1538-1145 |
| DOI: | 10.1097/pra.0000000000000403 |
| Popis: | Gabapentin is an anticonvulsant medication with an indication from the US Food and Drug Administration for use in partial onset seizures and postherpetic neuralgia in the United States. Currently, gabapentin is only classified as a controlled substance subject to stricter prescribing and distributing regulations in certain states, as opposed to pregabalin, an anticonvulsant with a similar mechanism of action which is a considered a Schedule V medication under federal law. Gabapentin shares a structural similarity to pregabalin, and several case reports have suggested that gabapentin has a similar propensity for abuse. The mechanisms of the gabapentin reward pathway, addiction, and withdrawal, however, are not well known. This case report describes a patient with long-term polysubstance abuse and new onset gabapentin dependence and demonstrates the need for increased surveillance of gabapentin prescribing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|